Coherus Rolls Out YUSIMRY At $995 Per Carton In US

RTTNews | 850 hari yang lalu
Coherus Rolls Out YUSIMRY At $995 Per Carton In US

(RTTNews) - Coherus BioSciences, Inc. (CHRS) announced Monday that YUSIMRY (adalimumab-aqvh) is now available for commercial sale in the United States at a list price of $995 per carton for two 40 mg/0.8 mL autoinjectors.

The pricing represents a discount of more than 85% to Humira (adalimumab), currently priced at $6,922 per carton of two pens.

YUSIMRY is presented in a state-of-the-art autoinjector and includes Coherus' proprietary non-stinging, citrate-free formulation and a 29-gauge needle.

YUSIMRY, approved in 2021 by the U.S. Food and Drug Administration, is a tumor necrosis factor blocker indicated to reduce the signs and symptoms of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis, and to treat Crohn's disease, ulcerative colitis, plaque psoriasis and hidradenitis suppurativa.

YUSIMRY Solutions - Coherus' patient services platform - will ensure improved access and a fast and seamless experience as patients start or switch to YUSIMRY treatment based on a determination by their healthcare provider.

read more
Coherus, Junshi Biosciences Say FDA Accepts Resubmission Of Toripalimab BLA

Coherus, Junshi Biosciences Say FDA Accepts Resubmission Of Toripalimab BLA

Coherus BioSciences, Inc. (CHRS) and Shanghai Junshi Biosciences Co., Ltd. announced Wednesday that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) resubmission for toripalimab in combination with gemcitabine and cisplatin as first-line treatment for patients with advanced recurrent or metastatic nasopharyngeal carcinoma (NPC) and for toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy.
RTTNews | 1212 hari yang lalu
Sensex, Nifty Modestly Higher In Early Trade

Sensex, Nifty Modestly Higher In Early Trade

Indian shares were slightly higher on Friday despite mixed cues from global markets. The benchmark BSE Sensex was up 180 points, or 0.2 percent, at 84,583 in early trade, while the broader NSE Nifty index edged up by 38 points, or 0.2 percent, to 25,915.
RTTNews | 6 minit yang lalu
Australian Market Trims Early Gains In Mid-market

Australian Market Trims Early Gains In Mid-market

The Australian stock market is trimming its early gains in mid-market moves on Friday, snapping a three-session losing streak, despite the broadly negative cues from Wall Street overnight. The benchmark S&P/ASX 200 is moving above the 8,900 level, with strong gains in gold miner stocks partially offset by weakness in technology stocks.
RTTNews | 1j 5min yang lalu
Asian Markets Trade Mixed

Asian Markets Trade Mixed

Asian markets are trading mixed on Friday, following the negative cues from Wall Street overnight, amid renewed uncertainty about the outlook for interest rates after Fed Chair Jerome Powell said a further reduction in rates in December is "not a foregone conclusion. Positive developments out of US President Donald Trump's meeting with Chinese President Xi Jinping is aiding market sentiment.
RTTNews | 1j 11min yang lalu
Japanese Market Sharply Higher

Japanese Market Sharply Higher

Extending the gains in the previous two sessions, the Japanese market is sharply higher on Friday, despite the broadly negative cues from Wall Street overnight. The Nikkei 225 is moving above the 52,200 level to fresh all-time highs, with gains in index heavyweights, exporters and technology stocks partially offset by weakness in automakers and financial stocks.
RTTNews | 2j 57min yang lalu
Australian Market Notably Higher

Australian Market Notably Higher

The Australian stock market is trading notably higher on Friday, snapping a three-session losing streak, despite the broadly negative cues from Wall Street overnight. The benchmark S&P/ASX 200 is moving above the 8,900 level, with gains in gold miners and financial stocks.
RTTNews | 3j 31min yang lalu